Michael Monrad Grandal

This inventor holds 8 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Les Laboratoires Servier, Symphogen A/s, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Monrad Grandal. Retrieved from https://idiyas.com/inventor/michael-monrad-grandal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 7.9

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

4 out of 296

Les Laboratoires Servier

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

patents

Years Active: 2019-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577302 - ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS (2026-03-17),

2. 12012450 - Anti-NKG2A antibodies and compositions (2024-06-18),

3. 11939380 - Combination therapies targeting PD-1, TIM-3, and LAG-3 (2024-03-26),

4. 11834503 - Anti-lag-3 antibodies and compositions (2023-12-05),

5. 11634500 - Anti-CD73 antibodies and compositions (2023-04-25),

6. 11390676 - Anti-LAG-3 antibodies and compositions (2022-07-19),

7. 11390674 - Anti-TIM-3 antibodies and compositions (2022-07-19),

8. 10450376 - Anti-MET antibodies and compositions (2019-10-22),

Title: The Innovative Contributions of Michael Monrad Grandal

Introduction

Michael Monrad Grandal is a notable inventor based in Ballerup, Denmark. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of seven patents to his name, Grandal's work focuses on enhancing immunity and developing therapies for cancer treatment.

Latest Patents

Among his latest patents are the "Anti-NKG2A antibodies and compositions," which relate to methods of using these antibodies to enhance immunity in patients and treat cancer. Another significant patent is for "Combination therapies targeting PD-1, TIM-3, and LAG-3." This invention involves using antibodies specific to these targets to improve immunity in patients, particularly those suffering from various cancers.

Career Highlights

Grandal has worked with prominent companies in the pharmaceutical industry, including Symphogen A/S and Les Laboratoires Servier. His experience in these organizations has allowed him to contribute to groundbreaking research and development in immunotherapy.

Collaborations

Throughout his career, Grandal has collaborated with talented individuals such as Michael Kragh and Mikkel Wandahl Pedersen. These partnerships have further enriched his work and expanded the impact of his inventions.

Conclusion

Michael Monrad Grandal's innovative patents and contributions to immunology highlight his role as a leading inventor in the field. His work continues to influence cancer treatment and enhance patient immunity.

Profile summary based on public USPTO records.